Long-term risk stratification for survivors of acute coronary syndromes: Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study

Journal of the American College of Cardiology

Volumn 38, Issue 1, 2001, Pages 56-63

  Marschner, Ian C ^a,i   Colquhoun, David ^b   John Simes, R ^a   Glasziou, Paul ^b   Harris, Philip ^c   Singh, Bhuwan B ^d   Friedlander, Denis ^e   White, Harvey ^f   Thompson, Peter ^g   Tonkin, Andrew ^h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d LAUNCESTON GENERAL HOSPITAL   (Australia)

^e WAIKATO HOSPITAL   (New Zealand)

^f GREEN LANE HOSPITAL   (New Zealand)

^g SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^h NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

ⁱ NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION;

AGED; ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PRAVASTATIN; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; SYNDROME;

EID: 0034964438     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01360-2     Document Type: Article

References (20)

1. Assessment of cardiovascular risk by use of multiple risk factor assessment equations
2. Prediction of coronary heart disease using risk factor categories
3. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention study
4. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: An updated Sheffield table
5. Optimal risk factor management in the patient after coronary revascularization
6. Preventing heart attack and death in patients with coronary heart disease
7. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia
8. Risk stratification in survivors of acute myocardial infarction: Routine cardiac catheterization and angiography is a reasonable approach in most patients
9. Primary prevention of coronary heart disease: Guidance from Framingham
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
11. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris
12. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge
13. Grading of angina pectoris
14. Revisions to classification of functional capacity and objective assessment of patients with diseases of the heart
15. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy
16. Cholesterol and coronary heart disease: Predicting risks by levels and ratios
17. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other societies on coronary prevention
18. Design, rationale and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project: A combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID), Cholesterol And Recurrent Events (CARE) and West of Scotland Coronary Prevention Study (WOSCOPS)